Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.66
Nov 20 • 3:59 PM ET Dollar change-0.16 Percentage change(-8.79%)
Aftermarket Close
1.66
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
5.60M
Enterprise Value
-1.24M
Income
-22.39M
Sales
1.17M
Book/sh
1.45
Cash/sh
2.15
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
38
IPO
Feb 12, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
4.79
P/B
1.15
P/C
0.77
P/FCF
-
EV/EBITDA
-
EV/Sales
-1.06
Quick Ratio
1.25
Current Ratio
1.25
Debt/Eq
0.09
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-8.13
EPS next Y
-5.95
EPS next Q
-2.00
EPS this Y
66.74%
EPS next Y
-38.69%
EPS next 5Y
23.52%
EPS past 3/5Y
47.61% 8.03%
Sales past 3/5Y
-0.63% -26.60%
EPS Y/Y TTM
39.19%
Sales Y/Y TTM
-18.93%
EPS Q/Q
51.39%
Sales Q/Q
-16.06%
Insider Own
21.55%
Insider Trans
0.00%
Inst Own
14.89%
Inst Trans
-15.35%
ROA
-162.40%
ROE
-305.10%
ROIC
-475.33%
Gross Margin
-17.51%
Oper. Margin
-2020.77%
Profit Margin
-1921.72%
SMA20
-18.20%
SMA50
-31.87%
SMA200
-73.97%
Trades
Shs Outstand
3.11M
Shs Float
2.65M
52W High
12.30 -86.50%
52W Low
1.31 26.72%
Volatility
12.73% 13.26%
ATR (14)
0.29
RSI (14)
39.51
Beta
0.80
Rel Volume
0.24
Avg Volume
115.83K
Volume
27,272
Perf Week
-33.33%
Perf Month
4.40%
Perf Quarter
-80.19%
Perf Half Y
-79.76%
Perf YTD
-67.19%
Perf Year
-72.49%
Perf 3Y
-99.14%
Perf 5Y
-99.83%
Perf 10Y
-
Prev Close
1.82
Price
1.66
Change %
-8.79%
Consensus
Hold
Avg. Price Target
$4.25
Implied Upside
+156.0%
Analysts1incl. previous ratings
Rating Distribution1 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Dec 06, 2024Initiated
RROTH MKM
Buy$10+502.4%
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.
M.D.Dr. Joshua Michael Hare FACC
General Counsel & SecretaryMr. Paul T. Lehr J.D.
CEO & DirectorMr. Stephen H. Willard Esq.
M.B.A.Mr. Nirav Suresh Jhaveri C.F.A.
CTO and Senior VP of ChemistryMr. Devin Blass